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Abstract
Introduction: Over the last decade, average life expectancy has continuously increased. There has been no data on normal sex hormone 
(SH) levels in a Polish elderly population. In this study, we assessed SH in the PolSenior cohort to determine normal reference ranges in 
relation to gender, age, and cardiovascular disease risk factors (CVDRFs).
Material and methods: The study was performed with 4,352 participants (2,168 men and 2,088 women), aged from 55 to over 90 years, 
stratified in five-year age groups. Pre-elderly subjects (55–59 years of age) served as the reference group. We assessed total testosterone 
(TT), estradiol (TE2) and DHEA-S (by RIA) SHBG and FSH (by IRMA) and calculated free androgen and free estrogen indices (FAI and 
FEI). Percentage body fat (%BF) was measured by bioelectric impedance analysis.
The CVDRFs assessment included blood pressure and biochemical (blood glucose, high-density lipoproteins, triglycerides) and anthro-
pometric (waist circumference) components of the metabolic syndrome. 
Results: TT was low in 19.9%, normal in 78.2%, and high in 1.8% of men. TE2 was low in 94.6% of women. Age and CVDRFs significantly 
influenced values of SHBG, FSH, TT, FAI, FEI, and DHEA-S in men, while in women values of FSH, TT and TE2 did not change. BMI and 
%BF affected SH regardless of the age groups and CVDRFs.
Conclusions: Our findings suggest that the reference ranges stratified by the five-year age bands seem more accurate than those given 
for the overall population over 60 years of age. The clinical relevance of these reference ranges increases when they are considered in 
relation to CVDRFs, BMI and %BF. (Endokrynol Pol 2013; 64 (2): 82–93)
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Streszczenie
Wstęp: W ostatniej dekadzie wzrasta przewidywana długość życia społeczeństw. W Polsce brak danych o stężeniach hormonów płcio-
wych (SH) u starzejących się osób. Celem naszej pracy było przedstawienie wartości referencyjnych SH w grupie osób uczestniczących 
w badaniu PolSenior w zależności od płci, wieku i czynników ryzyka chorób układu sercowo-naczyniowego (CVDRFs).
Materiał i metody: Badania wykonano u 4352 osób (2168 mężczyzn i 2088 kobiet) w wieku od 55. do powyżej 90. roku życia, podzielonych na 
5-letnie przedziały wieku. Osoby na przedpolu starości (wiek 55–59 lat) stanowiły grupę referencyjną. Oznaczano testosteron całkowity (TT), 
estradiol całkowity (TE2) i DHEAS metodami RIA, FSH i SHBG metodą IRMA wyliczono wskaźniki wolnych androgenów (FAI) i estrogenów 
(FEI). Odsetek tłuszczu ciała (%BF) oznaczano metodą bioimpedancji. CVDRFs analizowano w odniesieniu do wartości ciśnienia tętniczego 
oraz biochemicznych (stężenie glukozy, HDL i triglicerydów) i antropometrycznych (obwód talii) składowych zespołu metabolicznego. 
Wyniki: Prawie 20% mężczyzn miało stężenia TT poniżej normy, 78,2% w zakresie norm a 1,8% powyżej górnego zakresu normy. Stężenia 
TE2 poniżej normy dla kobiet po menopauzie miało 94,6% kobiet. Wiek i liczba CVDRFs istotnie zmieniały stężenia SH za wyjątkiem TE2 
u mężczyzn i FSH i TT u kobiet. BMI i %BF istotnie wpływało na większość oznaczanych hormonów niezależnie od wieku.
Wnioski: Przedstawiono wartości referencyjne dla stężeń SH u mężczyzn i kobiet od 65. do powyżej 90. roku życia. Nasze badania sugerują, 
że wartości referencyjne przedstawione w 5. letnich przedziałach wieku wydają się bardziej precyzyjne niż dla całej populacji powyżej 60. 
roku życia. Ich przydatność kliniczna zwiększa się, jeśli uwzględni się liczbę CVDRFs oraz BMI i %BF. (Endokrynol Pol 2013; 64 (2): 82–93)
Słowa kluczowe: testosteron, estradiol, wskaźniki wolnych hormonów, SHBG, DHEA-S, ludzie w podeszłym wieku, wartości referencyjne
Introduction
Over the last decade, average life expectancy has con-
tinuously increased. In Poland, compared to the middle 
of the last century, men live longer by approximately 
16 years and women by almost 19 years, including 
individuals over 60 years old. In 2010, the predicted 
life expectancy at age 75 was 9.47 years for men and 
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11.85 years for women [1]. Therefore, there have been 
increasing numbers of multidisciplinary studies aiming 
to assess the age-dependent health risk factors that af-
fect life expectancy in the elderly. The PolSenior Study is 
the first cross-sectional, national, and multicentre health 
survey designed to evaluate the medical, psychological, 
and socio-economic aspects of ageing in Poland [2].
The ageing process, which is still poorly understood, 
seems to be associated, among a variety of mechanisms, 
with a decline in the activity of the hypothalamic-pitu-
itary-gonadal axis in postmenopausal women, and, to 
a lesser extent, in men over 65 years old. Many symp-
toms observed in elderly people such as the decrease 
in physical activity associated with decline in muscle 
mass and the weakening of muscle contraction, mood 
changes, impaired cognitive processes, impaired sexual 
performance, increased rate of obesity and bone mass 
deterioration that lead to disability, may be associated, at 
least partially, with impaired gonad function. The main 
sex hormones, including testosterone in men and estro-
gen in women, are transported in the blood to target 
cells by carrier proteins, mainly by sex hormone-binding 
globulin (SHBG) and albumin. The sex hormones’ bio-
logical activity is associated with albumin-bound and 
albumin-free fractions that decide on their bioavail-
ability. In men over 60 years of age, the main sources of 
estrogens are the liver, skin, and adipose tissue, where 
biosynthesis of estrogen is based on aromatisation of 
their adrenal precursors [3]. In women, estrogens are 
synthesised also in ovarian theca cells [4].
The few studies performed on subjects aged 60–65 
years have demonstrated that, in men, SHBG levels 
increase and free testosterone (FT) decreases with age. 
The reports on total testosterone (TT) in men over 
65 have yielded conflicting results. Some studies have 
shown a progressive decrease in TT levels [5, 6], while 
others have not found significant age-dependent 
changes in TT [7, 8]. Similarly, there have been only 
a few studies that have provided inconsistent results 
regarding total estradiol (TE2) levels and free estradiol 
index (FEI) in ageing men [5]. 
In women over 60 years of age, as in men, studies 
have shown increases in SHBG levels with age [9, 10]. 
In women over 70 years of age, some studies have 
demonstrated decreases in TT, FT, and dehydroepian-
drosterone sulfate (DHEA-S) levels [11]. On the other 
hand, van Geel et al. [12] found that, in women aged 
55–84 years, SHBG, TT, FAI, and TE2 did not change, 
while FEI significantly decreased with age.
SHBG and sex hormone levels in the elderly are 
influenced by many factors. Aside from chronic 
kidney and liver diseases, obesity, thyroid diseases, 
hypopituitarism, dyslipidaemia, insulin resistance 
and type 2 diabetes, metabolic cardiovascular risk 
factors (CVDRFs), heart failure, and coronary heart 
disease may influence serum concentrations [13–15]. 
Increasing evidence suggests that the normal refer-
ence values for sex hormones in elderly subjects 
should be determined because they could help both 
in the assessment of hypogonadism rates [16] and 
in monitoring the safety and efficacy of hormone 
replacement therapy in elderly patients. 
In this study, we assessed sex hormone levels in the 
PolSenior cohort, stratified by five-year age groups, to 
determine reference ranges in relation to gender, age, 
and cardiovascular disease risk factors (CVDRFs).
Material and methods
Study population
This study was performed with 5,695 subjects (2,899 
men and 2,796 women) participating in the PolSenior 
Study, who were randomly selected from 16 adminis-
trative centres of Poland by the three-stage, propor-
tional, and stratified-by-age group selection process, 
as described elsewhere [2]. In brief, stratified random 
sampling was used with the aim of recruiting elderly 
men and women in six five-year age groups: 65–69, 
70–74, 75–79, 80–84, 85–89, and 90 years and over. Ad-
ditionally, from the same cohort, pre-elderly subjects 
aged 55–59 years served as the reference group. Sub-
jects were invited by letter to attend a session for an 
interviewer-administered questionnaire; assessment of 
height, weight, and waist and hip circumference, and 
blood sampling. The structured questionnaire (avail-
able at http://polsenior.iimcb.gov.pl/ankiety/) included 
details about medical history and socio-economic status 
of the subjects. Blood sampling, blood pressure and 
measurements of height, weight, waist circumference, 
and hip circumference were performed according to 
the standard protocol, as described elsewhere [17]. 
We included only those responders who were able to 
complete study procedures, and excluded immobilised 
patients.
The study complied fully with all applicable insti-
tutional and governmental regulations concerning the 
ethical use of human volunteers and with the terms of 
the Helsinki Declaration. The institutional review board 
approved the study protocol, and all the recruited sub-
jects gave their written informed consent.
Anthropometric measurements
Height, waist circumference (WC) and hip circumfer-
ence were measured to the nearest 0.5 cm. Percentage 
body fat (%BF) was measured by bioelectric impedance 
(Tanita BC-536, Tanita Corporation, Japan). %BF was 
calculated from the measurements of resistance made at 
50 kHz using the formula provided by the manufacturer.
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Assays
We collected blood samples from 2,168 men and 2,088 
women. Biochemical assessments included SHBG, FSH, 
TT, TE2, DHEA-S, lipid profiles, fasting glucose and insu-
lin were measured in all subjects in one batch of serum 
or plasma that had been thawed for the first time. Blood 
samples were divided in aliquots and frozen at –20°C 
until further analyses. Sex hormones, DHEA-S and insu-
lin were assessed by radioimmunological methods using 
Wallac 1470 Wizard gamma counter. SHBG and FSH were 
assessed by IRMA using commercially available assays 
(Immunotech, Prague). TT, TE2, DHEA-S, and insulin were 
assessed using the Siemens assays (Los Angeles, USA). 
The free androgen index (FAI) and FEI were calculated 
from SHBG, TT, and TE2 using the following formulas: 
FAI = TT(nmol/L) × 100/SHBG(nmol/L); FEI = 100 × 
E2 (pmol/L)/SHBG (nmol/L) [18, 19]. Blood glucose and 
lipid profiles, including total cholesterol, high-density 
lipoproteins (HDL), low-density lipoproteins (LDL) and 
triglycerides (TG) were assessed by automatic methods 
(Modular PPE, Roche Diagnostics). Insulin resistance 
was calculated from fasting glucose and insulin using 
the following formula: HOMA-IR (Homeostasis Model 
Assessment– Insulin Resistance) = glucose (mmol/L) × 
insulin (mIU/L)/22.5 [20]. 
The CVDRFs assessment included waist circumfer-
ence, blood pressure, blood glucose, HDL, and TG, 
according to current guidelines and diagnostic criteria 
for metabolic syndrome [21]. 
Statistical analysis
The distribution of continuous variables was tested for 
normality by the Kolmogorov-Smirnov test. Because 
the majority of the studied variables showed mark-
edly skewed distribution, logarithmic transformations 
of these measurements were performed before cal-
culations, and the results were presented as median 
(range), median (25–75 quartiles) or mean (95% CI). 
Differences among the groups were evaluated by 
Mann-Whitney U test or Wilcoxon signed rank test as 
appropriate. Intra-gender differences (between age 
bands, separately for men and women) were evaluated 
using ANOVA/MANOVA followed by Tukey’s post-hoc 
test. Linear Spearman’s rank correlation coefficients and 
multiple regression analyses were used to determine 
relationships between studied variables. We used the 
5% significance levels for all tests. All calculations were 
performed with the Statistica 9.0 software package 
(StatSoft, Tulsa, OK, USA).
Results
Baseline characteristics are shown in Table I. As ex-
pected, men had higher TE2, FEI and DHEA-S levels 
than women. They had also more favourable lipid 
profile. SHBG concentrations were comparable in both 
sexes. Medical history revealed that overall prevalence 
of known diabetes was 14.5% (308 subjects) in men and 
18% (396 subjects) in women. However, in the studied 
cohort, as many as 33.8% of individuals (1,202 men 
and women) had increased fasting glucose concentra-
tion, of whom nearly two thirds had glucose levels 
above 7.0 mmol/L (126 mg/dL). TT was low in 19.9%, 
normal in 78.2% and high in 1.8% of men compared 
to the normal reference range for men aged 60 years. 
Moreover, almost all men (99.6%) had TE2 levels below 
the normal reference range. On the other hand, only 
3.6% of females had TE2 levels above reference values 
for postmenopausal women. Compared to the normal 
reference ranges, TT was lowered in 46.5%, normal in 
50.1%, and increased in 3.4% of women. Sex hormones, 
SHBG, and DHEA-S significantly correlated with the 
majority of anthropometric and biochemical CVDRFs; 
the results of these analyses have been published else-
where [22].
The results of multiple regression analyses that as-
sessed the associations of sex hormones and DHEA-S 
with selected anthropometric (Model 1) and biochemi-
cal (Model 2) parameters as independent variables are 
shown in Table II. Sex hormones (except for FSH in 
women) and DHEA-S were strongly associated with 
age. 
Changes in SHBG, TT, FAI, FEI, FSH, and DHEA-S 
levels within age groups analysed by one-way ANOVA 
are shown in Table III and Figure 1. In men, compared 
to the pre-elderly and across some of the elderly age 
groups, mean values of FSH, TT, FAI, FEI, and DHEA-S 
decreased and SHBG increased. In women, as in men, 
SHBG increased and DHEA-S and free sex hormone 
indices decreased, while FSH and TT did not change 
with ageing. 
Among all the factors that influenced sex hormone 
levels, the majority were CVDRFs. Overall, more than 
three CVDRFs were present in as many as 41.4% of men 
and 58.6% of women. Although the majority of CVDRFs 
— adjusted for gender, age, and BMI — were strong 
single predictors of sex hormone levels in multiple 
regression analysis, further analyses using MANOVA 
revealed that, in women, only age (stratified by age 
groups) and number of CVDRFs (< 3 or ≥ 3) were sig-
nificant determinants of sex hormone levels (Table IV, 
Figure 2). In contrast, in men, the number of CVDRFs 
and age were associated with sex hormone levels only 
in a MANOVA model that also included %BF (p = 0.04). 
In women, %BF (< 30% or ≥ 30%) was a third factor 
that significantly modified sex hormone levels. 
 Median values of SHBG, TT, FAI, TE2, FEI and 
DHEA-S in subjects with more and less than three 
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CVDRFs are given in Table V. In both genders, all stud-
ied parameters (except for estradiol in men) significantly 
differed between subjects with ≥ 3 and < 3 CVDRFs. 
Sex hormones and SHBG concentrations significantly 
changed with age in men; however, changes in SHBG 
and FEI were more pronounced in individuals with 
more than three CVDRFs. FSH and TT in women did 
not change with age, and CVDRFs and individual 
significant changes in other parameters were not ob-
served in all age groups. Overall, we found significant 
differences in sex hormone levels (except FSH and 
TT) between women with less and more than three 
CVDRFs, but these differences were less pronounced 
than in men (Fig. 2). 
In univariate analysis, the associations of BMI and 
%BF with SHBG, FSH, FEI, and DHEA-S, although 
statistically significant, explained only a small percent-
age of the variation in sex hormones, except for SHBG 
level. In women, as in men, BMI markedly influenced 
the variation in SHBG. However, the impact of BMI on 
variations in other sex hormones (including FAI) was 
relatively low (Table VI). 
Discussion
In this study, we determined, for the first time, refer-
ence ranges for SHBG, TT, TE2, FAI, FEI, FSH, and 
DHEA-S in Polish men and women over 65 years of 
age, stratified by five-year age groups and including 
subjects over 90 years of age. In the literature, there 
have been only a few reports on the reference values 
of sex hormones in people over 65 years of age [5, 11, 
23–25]. In our study, sex hormone levels showed high 
individual variations, which has also been reported in 
earlier studies [5, 23]. These variations may result, at 
least partially, from the relatively less strict inclusion 
criteria applied in our study. However, they may also 
result from well-known environmental and metabolic 
factors as well as less-known genetic factors, which 
account for approximately 30-60% of the variation in 
Table I. Baseline characteristics. Values are expressed as median and Q25–Q75
Tabela I. Charakterystyka badanych. Wartości przedstawiono jako mediana i Q25–Q75
Men
(n = 1,649)
Women
(n = 1,547)
Z test
Age (years) 76.0 [69.0–85.0] 74.0 [67.0–83.0] ns
Height [cm] 170.0 [164.0–173.6] 156.0 [152.0–161.0] p < 0.000
Body mass [kg] 77.7 [69.0–87.2] 69.5 [60.4–80.0] p < 0.000
Waist circumference [cm] 100.0 [93.0-109.0] 96.0 [87 0–105.0] p < 0.000
Hip circumference [cm] 104.0 [100.0–110.0] 108.0 [101.0–116.0] p < 0.02
BMI [kg/m2] 27.2 [24.6–30.1] 28.3 [ 25.1–32.4] p < 0.000
 %BF 27.7 [22.6–32.9] 37.4 [31.8–41.9] p < 0.000
SHBG [nmol/L] 51.7 [38.6–70.2] 58.2 [41.8–80.8] ns
FSH [IU/L] 10.1 [6.4–19.5] 59.7 [44.0–75.0] p < 0.000
TT [ nmol/L] 15.3 [11.3–19.4] 0.8 [0.4–1.1] p < 0.000
FAI 29.8 [21.7–39.6] 1.3 [0.7–2.2] p < 0.000
TE2 [pmol/L] 48.4 [36.0–63.4] 23.8 [18.3–31.2] p < 0.000
FEI 91.6 [59.3–141.2] 41.3 [26.1-66.2] p < 0.000
DHEA-S [mg/dL] 766.0 [463.0–1,169.0] 543.0 [335.0–886.0] p < 0.001
 Total cholesterol (TC) [mmol/L] 5.1 [4.3–5.8] 5.5 [4.7–6.3] p < 0.004
LDL [mmol/L] 2.9 [2.3–3,7] 3.2 [2.5–4.0] ns
HDL [mmol/L] 1.2 [0.9–1,5] 1.4 [1.1–1.6] p < 0.000
Triglycerides (TG) [mmol/L] 1.2 [0.9–1.6] 1.4 [1.1–1.82] p < 0.000
Glucose [mmol/L] 5.3 [4.8–6.1] 5.2 [4.8–5.9] ns
Insulin [mIU/L] 5.1 [2.8–9.4] 6.3 [3.6–10.6] ns
HOMA IR 1.2 [0.6–2.4] 1.5 [0.8–2.7] ns
Diabetes (%) 14.5 18.0
Hypertension (%) 57.0 41.3
Z — Wald-Wolfowitz test
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SHBG [26] — a globulin that determines both binding 
and bioavailability of sex hormones. We have demon-
strated that, compared to the pre-elderly and across the 
elderly age groups, mean values of TT, DHEA-S, FAI, 
and FEI decreased, SHBG increased, and TE2 decreased 
only in men over 85 years of age. In women, as in men, 
SHBG increased, free sex hormones indices and DHEA-
S decreased, but TT, FSH and TE2 (except for women 90 
years of age) did not change with age. Overall, these 
findings are consistent with the results of earlier studies 
[5, 7], although, unlike our study, they could not find 
any associations between age and TT in men. We also 
confirmed previous reports that have found increases 
in SHBG levels with age in women [9, 10]. On the other 
hand, in line with some studies [11, 12], but in contrast 
to other studies [24, 23], we could not demonstrate the 
impact of ageing on TT levels in women. As in men, we 
observed age-dependent decreases in DHEA-S, FAI, 
and FEI in women. These discrepancies may result from 
differences in methods of hormone assessment and 
their free fraction calculation, ethnicity, age of studied 
populations, and sample size. 
The cross-sectional nature of our study does not 
allow exploration of a cause-effect relationship; thus, 
our results do not explain age-dependent increases in 
SHBG levels in the ageing population. However, our 
results seem to confirm that some of these changes 
might be associated with changes in insulin sensitivity 
and BMI, which progressively decrease with age (data 
not shown). Free sex hormones indices seem to reflect 
changes in SHBG levels. Moreover, the progressive 
FSH increase and TT decrease observed in our study 
may suggest that the age-related decline of gonadal 
function in elderly men is rather a slow process, while 
in women, the pituitary-gonadal axis seems to remain 
relatively stable throughout the entire postmenopausal 
period up to 85 years of age. 
Our results suggest that both in men and women, 
CVDRFs may influence sex hormone levels. Men 
with more than three CVDRFs had decreased values 
of SHBG and TT, higher FAI and FEI, but similar TE2 
compared to those with fewer CVDRFs. These findings 
are consistent with the majority of previous studies [8, 
9, 27] and Maggio et al. [28], who found lowered TE2 
concentration in older men in the InCHIANTI Study. 
In our study, women with three or more CVDRFs, like 
men, had lowered SHBG levels but higher TT, TE2, and 
FAI, which has also been reported by previous stud-
ies [9, 29] and confirmed in a recent meta-analysis of 
52 observational studies [27]. In addition to these ob-
servations, we also found in this population higher FEI 
and DHEA-S concentrations. 
Based on our results and the results of previ-
ously cited reports, we present, for the first time in Ta
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Table IIIA. Mean and 95% confidence intervals (antilogarithms) values of SHBG, FSH, TT, FAI, TE2, FEI and DHEA-S levels 
in five-year age bands in men
Tabela IIIA. Średnie i 95% przedziały ufności (antylogarytmy) stężenia SHBG, FSH, TT, FAI, TE2, FEI i DHEA-S w 5-letnich 
przedziałach wiekowych u mężczyzn 
Age group 
(years)
n SHBG 
[nmol/L]
FSH 
[UI/L]
TT 
[nmol/L]
FAI E2 
[pmol/L]
FEI DHEA-S 
[ng/mL]
55–59 233 41.6 6.9 16.1 38.6 50.8 122.0 1,397.8
39.3–44.1 6.3–1.1 14.6–17.1 35.0–42.6 47.8–53.9 112.5–132.4 1,288.2–1,516.8
65–69 273 45.3 8.5 15.7 34.6 49.0 108.0 973.1***
42.0–47.9 7.7–9.3 14.3–17.2 31.5–38.1 446.2–51.9 99.8–116.8 899.1–1,053.2
70–74 317 50.3*** 10.1 14.2 28.2** 46.6 92.6*** 802.8***
47.7–53.0 9.2–11.1 13.0–15.5 25.8–30.9 44.1–49.2 85.9–99.8 744.4–865.8
75–79 312 53.2*** 12.1*** 15.0 28.2** 49.3 92.6*** 737.9***
50.6–56.0 11.0–13.2 13.8–16.4 25.8–30.8 46.7–52.0 86.1–99.5 685.9–793.8
80–84 286 57.0*** 13.1*** 12.5*** 22.0*** 45.3 79.4*** 590.1***
53.9–60.3 11.9–14.5 11.4–13.8 19.9–24.2 42.7–48.1 73.3–86.1 544.1–640.0
85–89 315 61.7*** 17.1*** 10.8*** 17.6*** 44.4** 72.0*** 510.6***
65.0–65.0 15.6–18.8 9.9–11.9 16.0–19.2 42.0–47.0 66.8–77.6 473.5–550.6
 > 90 219 68.5*** 22.8*** 9.5*** 13.8*** 41.4** 60.5 408.1
64.5–72.6 20.6–25.3 8.5–10.5 12.5–15.3 38.9–44.1 55.6–65.8 374.8–444.3
p  (ANOVA) p < 0.000 p < 0.000 p < 0.000 p < 0.000 p < 0.000 p < 0.000 p < 0.000
Differences in serum SHBG, FSH, TT, FAI, TE2, FEI, and DHEA-S levels between age groups were calculated using Tukey’s post hoc test ; **p > 0.00 v. group of 55–59 
year; ***p > 0.000 v. group of 55–59 year
Table IIIB. Mean and 95% confidence intervals (antilogarithms) values of SHBG, FSH, TT, FAI, TE2, FEI, and DHEA-S in 
five-year age bands in women
Tabela IIIB. Średnie i 95% przedziały ufności (antylogarytmy) stężenia SHBG, FSH, TT, FAI, TE2, FEI i DHEA-S w 5-letnich 
przedziałach wiekowych u kobiet
Age group 
(years)
n SHBG 
[nmol/L]
FSH 
[IU/L]
TT 
[nmol/L]
FAI E2 
[pmol/L]
FEI DHEA-S 
[ng/mL]
55–59 288 49.7 56.3 0.72 1.45 26.5 53.2 779.6
47.1–52.4 52.8–60.1 0.66–0.79 1.31–1.61 25.1–27.9 49.1–57.6 719.4–844.8
65–69 285 51.9 55.5 0.71 1.37 24.6 47.4 647.2***
49.0–55.0 51.7–59.5 0.65–0.78 1.23–1.53 23.2–26.0 43.4–51.6 593.4–706.0
70–74 319 55.8 56.3 0.75 1.34 23.8 42.7 534.0***
52.7–59.1 52.5–60.3 0.68–0.82 1.21–1.50 22.5–25.2 39.2–46.6 489.9–582.2
75–79 262 59.3*** 49.4 0.72 1.21 24.4 41.2*** 451.3***
55.8–63.1 45.8–53.2 0.65–0.80 1.08–1.36 23.0–26.0 37.6–45.1 411.4–494.9
80–84 223 65.6*** 53.7 0.70 1.06* 23.1 35.2*** 395.9***
61.6–70.0 49.7–58.0 0.63–0.77 0.94–1.19 21.7–24.6 32.0–38.7 359.7–435.8
85–89 237 71.8*** 53.9 0.71 0.99*** 23.3 32.4*** 444.0***
67.6–76.3 50.0–58.0 0.64–0.78 0.88–1.11 21.9–24.8 29.6–35.5 405.3–486.4
 > 90 201 80.0*** 59.4 0.74 0.93*** 22.2* 27.8*** 378.4***
75.0–85.3 55.0–64.2 0.67–0.83 0.82–1.05 20.8–23.7 25.2–30.5 343.7–416.6
p  (ANOVA) p = 0.000 p = 0.0799 p = 0.8903 p = 0.002 p = 0.000 p = 0.000 p = 0.000
Differences in serum SHBG, FSH, TT, FAI, TE2, FEI, and DHEA-S levels between age groups were calculated using Tukey’s post hoc test ; *p < 0.05 v. group of 55–59 yr;  
***p < 0.000 v. group of 55–59 yr
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Figure 1A. Distribution of values of SHBG, FSH, TT, FAI, FEI and DHEA-S concentrations (mean and 95% CI; logarithms) by age 
groups in men. TE2 decreased significantly only in subjects aged > 85 (not shown); B. Distribution of values of SHBG, FSH, FAI, TE2, 
FEI and DHEAS concentrations (mean and 95% CI; logarithms) by age groups in women. FSH and TT (not shown) did not change. 
TE2 decreased significantly only in subjects aged > 90
Rycina 1A. Rozkład stężeń SHBG, FSH, TT, FAI, FEI i DHEA-s ( średnia i 95% CI; logarytmy) w grupach wieku u mężczyzn. Stężenia TE2 zmniejszały 
się tylko u osób > 85. roku życia (nie przedstawione); B. Rozkład stężeń SHBG, FSH, FAI, TE2 , FEI i DHEA-S (średnia i 95% CI; logarytmy) w 
grupach wieku u kobiet. Stężenia FSH i TT (nie przedstawione) nie zmieniały się. Stężenia TE2 zmniejszały się istotnie dopiero > 90. roku życia
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Table IVA. Mean and 95% confidence intervals (antilogarithms) values of SHBG, FSH, TT, FAI, TE2, FEI and DHEA-S in five-
year age bands in men with CVDRF < 3 and CVDRF ≥ 3. Differences between age groups were calculated using Tukey’s post 
hoc test. MANOVA; the Wilks test = 0.97; p = 0.04
Tabela IVA. Średnie i 95% przedziały ufności (antylogarytmy) stężenia SHBG, FSH, TT, FAI, TE2, FEI i DHEA-S w 5-letnich 
przedziałach wiekowych u mężczyzn z CVDRF < 3 i CVDRF ≥ 3. Różnice między przedziałami wieku oceniano testem post 
hoc Tukey’a. MANOVA; test Wilksa = 0.97; p = 0.04
Age group  
(years)
n SHBG 
[nmol/L]
FSH 
[IU/L]
TT 
[mmol/L]
FAI TE2 
[pmol/L]
 FEI DHEAS 
[ng/mL]
CVDRF < 3
55–59 122 52.7 7.3 19.7 37.4 52.9 100.3 1,401.8
48.4–57.5 6.2–8.6 16.9–23.0 32.0–43.8 48.1–58.3 88.3–114.0 1,231.2–1,596.1
65–69 113 53.6 8.6 16.7 31.1 46.6 87.0 969.6
48.6–59.1 7.2–10.3 14.0–19.9 26.0–37.2 41.8–52.0 75.2–100.5 836.5–1,123.7
70–74 144 63.2 9.6 17.6 27.9 44.7 70.8 767.6
58.0–68.8 8.3–11.3 15.2–20.5 23.9–32.6 40.7–49.2 62.4–80.3 675.1–872.8
75–79 146 59.8 11.0 18.2 30.3 55.8 93.2 774.2
54.1–66.2 9.2–13.3 15.2–21.7 25.3–36.4 49.9–62.3 80.4–108.0 666.3–899.6
80–84 134 62.2 12.6 12.9 20.7 44.0 70.7 582.6
57.4–67.4 10.9–14.7 11.1–14.8 17.8–23.9 40.2–48.1 62.7–79.6 516.1–657.6
85–89 173 68.2 15.7 13.1 19.1 44.7 65.4 500.4
63.5–79.6 13.8–17.9 11.5–14.8 16.8–21.8 41.2–48.4 58.8–72.8 449.1–557.6
 > 90 122 70.9 23.0 10.2 14.3 45.0 63.5 392.5
65.3–76.9 19.8–26.7 10.2–11.7 12.4–16.6 41.1–49.3 56.3–71.6 347.4–443.5
CVDR ≥ 3
55–59 92 31.1 5.8 12.2 39.2 56.4 181.8 1,229.7
25.8–37.5 4.1–8.2 8.8–17.0 27.9–55.1 45.9–69.5 138.0–239.5 928.8–1,628.0
65–69 126 48.4 8.0 16.3 33.7 55.6 114.8 1,286.0
39.4–59.5 5.5–11.6 11.3–23.5 23.2–49.1 44.2–69.9 84.7–155.7 943.2–1,753.5
70–74 145 47.0 9.2 14.4 30.6 48.6 103.5 671.4
41.4–53.4 7.3–11.6 11.5–18.0 24.3–38.6 42.2–56.1 85.7–124.9 554.5–813.0
75–79 130 49.1 11.6 15.6 31.7 50.9 103.7 666.0
41.4–58.2 8.5–15.8 11.5–21.0 23.3–43.2 42.2–61.5 80.7–133.2 516.0–859.4
80–84 111 54.6 12.8 12.6 23.1 50.7 92.8 447.2
46.0–64.8 9.4–17.5 9.3–17.1 17.0–31.5 41.9–61.3 72.1–119.3 346.2–577.8
85–89 97 50.2 14.5 8.6 17.1 45.5 90.7 497.3
42.3–59.6 10.6–19.8 6.4–11.7 12.6–23.4 37.6–55.1 70.4–116.7 384.5–643.1
 > 90 43 61.9 13.2 5.1 8.3 33.2 53.7 453.0
48.5–79.0 8.5–20.7 3.3–7.9 8.3–12.9 25.4–43.6 37.5–76.8 314.4–652.7
the literature, reference ranges for SHBG, TT, TE2, 
DHEA-S, FSH, FAI, and FEI in elderly Polish men 
and women, stratified by five-year age groups and 
number of CVDRFs. Our results suggest that the 
reference ranges for sex hormones are not only gen-
der- and age-specific, but also should be evaluated in 
relation to the number of CVDRFs. In particular, this 
might facilitate decisions regarding the application of 
hormone replacement therapy in elderly cases with 
hypogonadism.
The strength of this study is that we analysed 
a large, representative, randomly selected sample 
of elderly Polish people recruited from different ad-
ministrative centres of Poland using the three-stage, 
proportional and stratified-by-age group selection 
process. However, some potential limitations should 
be considered in interpreting our results. First, the 
cross-sectional nature of the study is problematic for 
differentiating cause and effect from simple associa-
tion. Second, we did not use strict exclusion criteria, 
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which might have potentially influenced the vari-
ability of hormonal assessments. Like Orwoll et al. 
[5] and Yeap et al. [7], we did not exclude cases with 
benign prostatic hyperplasia (2.5% of men in the 
PolSenior cohort), prostate cancer (0.85%) that might 
be treated with antiandrogens [30], or hypothyroid-
ism (10.3% of women and 5.6% of men, including 
60% with asymptomatic disease) [31]. We also did not 
exclude patients with diabetes because in the multiple 
regression analysis, history of diabetes, along with 
BMI and age bands, did not significantly influence 
sex hormone levels (data not shown). Third, in this 
study we evaluated TT with the RIA method. It has 
been suggested that liquid chromatography-mass 
spectrometry has the highest sensitivity and selectiv-
ity in the determination of total and free testosterone. 
However, recent studies have not shown significant 
advantages for either method [32]. 
In conclusion, in this study, we have presented nor-
mal reference values for sex hormones in Polish elderly 
Table IVB. Mean and 95% confidence intervals (antilogarithms) values of SHBG, FSH, TT, FAI, TE2, FEI, and DHEA-S in 
five–year age groups in women with CVDRF < 3 and CVDRF ≥ 3. Differences between age groups were calculated using Tukey’s 
post hoc test. MANOVA; the Wilks test = 0.97; p = 0.004
Tabela IVB. Średnie i 95% przedziały ufności (antylogarytmy) stężenia SHBG, FSH, TT, FAI, TE2, FEI i DHEA-S w 5–letnich 
przedziałach wiekowych u kobiet z CVDRF < 3 i CVDRF ≥ 3. Różnice między przedziałami wieku oceniani testem post hoc 
Tukey’a. MANOVA: test Wilksa = 0.97; p = 0,004
Age group ) 
[years]
n log SHBG 
[nmol/L]
log FSH 
[IU/L]
log TT 
[nmol/L]
log FAI 
[nmol/L]
log E2  
[pmol/L]
log FEI log DHEAS 
[ng/mL]
CVDRFs < 3
55–69 148 56.1 58.7 0.67 1.19 25.9 46.1 770.7
52.1–60.5 53.6–64.2 0.6–0.8 1.03–1.36 24.0–27.9 41.2–51.5 689.0–862.1
65–69 90 56.7 58.7 0.76 1.34 24.1 42.5 686.1
51.4–62.4 52.3–65.9 0.6–0.9 1.12–1.60 21.9–26.5 36.8–49.0 594.3–792.1
70–74 85 63.3 59.0 0.77 1.22 22.5 35.6 539.7
57.4–69.8 52.4–66.5 0.7–0.9 1.02–1.47 20.4–24.8 30.7–41.2 465.5–625.7
75–79 77 65.5 47.0 0.70 1.08 24.9 38.1 404.2
59.1–72.6 41.5–53.3 0.6–0.8 0.89–1.31 22.5–27.6 32.6–44.4 346.0–472.1
80–84 77 68.1 51.3 0.64 0.93 22.6 33.2 353.0
61.5–75.5 45.3–58.2 0.5–0.8 0.77–1.13 20.4–25.1 28.4–38.7 302.3–412.4
85–89 90 74.0 56.1 0.68 0.91 23.3 31.4 410.4
67.3–81.4 50.0–63.0 0.6–0.8 0.76–1.09 21.1–25.6 27.3–36.2 355.5–473.8
 > 90 97 83.7 63.0 0.70 0.83 19.9 23.8 336.3
76.4–91.8 56.3–70.4 0.6–0.8 0.70–0.99 18.2–21.8 20.7–27.3 292.9–386.3
CVDRFs ≥ 3
55–59 140 44.0 54.1 0.78 1.78 27.1 61.5 788.6
40.8–47.5 49.3–59.4 0.7–0.9 1.54–2.05 25.1–29.2 54.8–68.9 702.8–884.0
65–69 195 47.5 52.5 0.67 1.40 25.1 52.8 610.5
44.5–50.7 48.5–56.8 0.6–0.7 1.24–1.59 23.5–26.8 47.9–58.2 553.8–673.1
70–74 234 49.1 53.6 0.72 1.47 25.2 51.4 528.5
46.3–52.1 49.9–57.6 0.7–0.8 1.32–1.65 23.8–26.8 47.0–56.1 483.4–577.7
75–79 185 53.7 51.8 0.73 1.37 23.9 44.5 503.8
50.3–57.4 47.8–56.2 0.7–0.8 1.21–1.55 22.4–25.5 40.3–49.1 455.7–556.9
80–84 146 63.2 56.2 0.76 1.20 23.7 37.4 444.0
58.7–68.2 51.3–61.5 0.7–0.9 1.04–1.38 22.0–25.5 33.5–41.8 296.7–497.1
85–89 147 69.7 51.7 0.74 1.07 23.3 33.5 480.3
64.6–75.1 47.2–56.6 0.7–0.8 0.93–1.23 21.7–25.1 30.4–37.5 429.2–537.4
 > 90 104 76.4 56.1 0.79 1.04 24.8 32.4 425.7
70.0–83.5 50.4–62.5 0.7–0.9 0.88–1.23 22.7–27.1 28.4–37.0 372.4–486.5
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Figure 2A (men), B (women) — Distribution of sex hormones SHBG and DHEA-S concentrations (mean and 95% CI; logarithms) 
by age groups in persons with CVDRFs < 3 and CVDRFs ≥ 3
Rycina 2A (mężczyźni), B (kobiety) — Rozkład stężeń hormonów płciowych, SHBG i DHEA-S w grupach wieku (średnia i 95% CI; 
logarytmy) u osób mających < 3 CHDRFs oraz ≥ 3 CHDRFs
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Table V. Median values (range) of SHBG, TT, FAI, TE2, FEI, FSH, and DHEA-S concentrations in men and women with CVDRF 
< 3 and CVDRF ≥ 3
Tabela V. Mediany (rozstęp) stężeń SHBG, TT, FAI, TE2 ,FEI, FSH i DHEA-S u mężczyzn i kobiet z liczbą czynników ryzyka 
sercowo-naczyniowego poniżej 3 i powyżej 3 (CVDRF < 3 i CVDRF ≥ 3)
Men p Women p
CVDRFs < 3 CVDRFs ≥ 3 CVDRFs < 3 CVDRFs ≥ 3
SHBG [nmol/L] 60.1 (321.7) 45.4 (215.9) p = 0.000 65.5 (226.2) 54.9 (228.8) p = 0.000
FSH [IU/L] 10.7 (166.6) 9.7 (106.9) p = 0.002 63.2 (210.7) 57.6 (275.7) p = 0.000
TT [ nmol/L] 16.2 (62.9) 14.0 (36.9) p = 0.000 0.7 (27.2) 0.8 (65.8) p = 0.04
FAI 28.3 (124.9) 31.4 (119.3) p = 0.000 1.1 (38.8) 1.3 (89.4) p = 0.000
E2 [pmol/L] 47.7 (231.2) 48.8 (261.0) ns 22.7 (367.0) 24.2 (472.3) p = 0.002
FEI 79.1 (595.1) 105.9 (715.6) p = 0.000 34.2 (398.2) 43.9 (624.2) p = 0.000
DHEA–S [mg/dL] 723.0 (6,473.0) 772.0 (4,942.0) p = 0.007 503.0 (4,100.0) 554.0 (4,786.0) p = 0.02
Table VI. Associations between BMI, %BF, SHBG, TT, FAI, TE2, FEI, FSH, and DHEA-S in men and between BMI, SHBG, 
TT, FAI, TE2, FEI, FSH, and DHEAS in women
Tabela VI. Zależności między BMI, BF%, SHBG, TT, FAI, TE2, FEI, FSH i DHEA-S u mężczyzn oraz BMI, SHBG, TT, FAI, 
TE2, FEI, FSH i DHEA-S u kobiet 
log BMI
Men β SE p R2 The regression equation
SHBG [nmol/L] –1.00 0.06 0.000 0.12 log SHBG = 3.15–1.00 * log BMI
FSH [IU/mL] –0.44 –0.44 0.000 0.01 log FSH = 1.65–0.44 * log BMI
TT [nmol/L] –0.51 0.11 0.000 0.01 log TT = 1.84–0.51* log BMI
FAI 0.51 0.11 0.000 0.01 log FAI = 0.67 + 0.51* log BMI
TE2 [pmol/L] 0.09 0.07 ns
FEI 1.11 0.09 0.000 0.07 log FEI = 0.365 + 1.10* log BMI
DHEAS [ng/mL] 0.39 0.10 0.000 0.01 log DHEAS = 2.28 + 0.39 * log BMI
log %BF
Men β SE p R2 The regression equation
SHBG [nmol/L] –0.40 0.04 0.000 0.07 log SHBG = 2.29–0.40 * log %BF
FSH –0.17 0.06 0.008 0.00 log FSH = 1.30–0.17 * log %BF
TT [nmol/L] –0.31 0.06 0.000 0.01 log TT = 1.57–0.31* log %BF
FAI 0.09 0.06 ns
TE2 [pmol/L] –0.03 0.04 ns
FEI 0.38 0.05 0.000 0.03 log FEI = 1.40 + 0.38 * log %BF
DHEAS [ng/mL] 0.14 0.06 0.011 0.00 log DHEAS = 2.66 + 0.14 * %BF
log BMI
Women β SE p R2 The regression equation
SHBG [nmol/L] –0.97 0.06 0.000 0.13 log SHBG = 3.19–0.97 * log BMI
FSH [IU/L] –0.58 0.07 0.000 0.04 log FSH = 2.57–0.58 * log BMI
TT [nmol/L] 0.28 0.09 0.002 0.00 log TT = –0.51 + 0.28 * log BMI
FAI 1.25 0.10 0.000 0.07 log FAI = –1.701 + 1.2295 * log BMI
TE2 [pmol/L] 0.50 0.06 0.000 0.04 log E2 = 0.61 + 0.50 * log BMI
FEI 1.48 0.08 0.000 0.14 log FEI = –0.57 + 1.48 * log BMI
DHEAS [ng/mL] 0.27 0.09 0.004 0.00 log DHEAS = 2.37 + 0.27 * log BMI
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men and women. Our data suggests that the reference 
ranges stratified by five-year age bands seem more ac-
curate than those given for the overall population over 
60 years of age. The clinical relevance of these reference 
ranges increases when they are considered in relation 
to CVDRFs, BMI, and %BF.
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